Bladder Cancer

July 17th 2024

Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.

June 28th 2024

Vikram Narayan, MD, discussed the durable clinical activity observed with nadofaragene firadenovec in the CS-003 trial for patients with non-muscle invasive bladder cancer.

June 25th 2024

Combining durvalumab with chemotherapy in the NIAGARA trial led to significant improvements in event-free survival and overall survival for patients with muscle-invasive bladder cancer.

June 24th 2024

In this feature article, key opinion leaders look at the burgeoning use of ctDNA to dictate treatment approaches for patients with bladder cancer.